BioXcel Therapeutics Reports Positive Phase 2 Results for Opioid Withdrawal Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BTAI?
Source: Benzinga
- Clinical Trial Results: BioXcel Therapeutics' Phase 2 study indicates that BXCL501 is as effective as or superior to BioCorRx's lofexidine in reducing opioid withdrawal symptoms, with a more convenient dosing regimen potentially offering better treatment options for patients.
- Significant Symptom Improvement: Patients receiving BXCL501 240 µg experienced over a 30% reduction in Short Opiate Withdrawal Scale (SOWS-Gossop) scores, with peak symptom improvement observed on days 3 and 4, demonstrating BXCL501's efficacy.
- Good Tolerability Profile: BXCL501 showed a favorable tolerability profile compared to lofexidine, with similar or lower rates of cardiovascular side effects, indicating higher safety in clinical applications.
- Huge Market Potential: BXCL501 is viewed as a “pipeline within a product,” with applicability potentially extending to acute agitation associated with bipolar disorder and schizophrenia, signaling future market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTAI
Wall Street analysts forecast BTAI stock price to rise
2 Analyst Rating
1 Buy
0 Hold
1 Sell
Hold
Current: 1.610
Low
1.00
Averages
5.50
High
10.00
Current: 1.610
Low
1.00
Averages
5.50
High
10.00
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BIOXCEL THERAPEUTICS STOCK INCREASES 2.7% FOLLOWING POSITIVE RESULTS FROM MID-STAGE TRIAL OF EXPERIMENTAL OPIOID WITHDRAWAL TREATMENT
Stock Performance: BioXcel Therapeutics shares have increased by 2.7%.
Clinical Trial Results: An experimental opioid withdrawal drug shows benefits in mid-stage trials.
See More
BioXcel Therapeutics Shares Decline Despite Positive Drug Development News
- Drug Development Progress: BioXcel Therapeutics' BXCL501 demonstrated efficacy in a Phase 2 study led by Columbia University for treating opioid withdrawal symptoms, with over a 30% reduction in symptoms observed in patients, indicating the drug's potential across multiple indications.
- Stock Price Analysis: Despite the positive results from BXCL501, BioXcel's shares are currently priced at $1.52, trading 3.9% below the 20-day simple moving average and 17.9% below the 100-day SMA, indicating a lack of upward momentum in the short term.
- Long-term Performance Weakness: The stock has decreased approximately 41.24% over the past 12 months and is closer to its 52-week lows, reflecting market concerns about its future performance, although the relative strength index (RSI) at 46.86 suggests a neutral state.
- Market Sentiment Analysis: While the overall trend is bearish, the MACD at -0.0166 is above its signal line, indicating some bullish momentum that may present short-term trading opportunities for investors.
See More
BioXcel Therapeutics Reports Positive Phase 2 Results for Opioid Withdrawal Treatment
- Clinical Trial Results: BioXcel Therapeutics' Phase 2 study indicates that BXCL501 is as effective as or superior to BioCorRx's lofexidine in reducing opioid withdrawal symptoms, with a more convenient dosing regimen potentially offering better treatment options for patients.
- Significant Symptom Improvement: Patients receiving BXCL501 240 µg experienced over a 30% reduction in Short Opiate Withdrawal Scale (SOWS-Gossop) scores, with peak symptom improvement observed on days 3 and 4, demonstrating BXCL501's efficacy.
- Good Tolerability Profile: BXCL501 showed a favorable tolerability profile compared to lofexidine, with similar or lower rates of cardiovascular side effects, indicating higher safety in clinical applications.
- Huge Market Potential: BXCL501 is viewed as a “pipeline within a product,” with applicability potentially extending to acute agitation associated with bipolar disorder and schizophrenia, signaling future market opportunities.
See More
BioXcel Therapeutics Reports Positive Phase 2 Trial Results for Opioid Withdrawal Treatment
- Clinical Trial Results: BioXcel Therapeutics announced positive topline results from a Phase 2 trial involving 80 patients, where BXCL501 demonstrated a significant reduction of over 30% in opioid withdrawal symptoms, indicating its potential effectiveness comparable to or better than FDA-approved lofexidine, thereby strengthening the company's competitive position in the market.
- Notable Treatment Effects: The most significant symptom improvement was observed on days three and four of treatment, which not only enhances BXCL501's clinical application potential but may also increase its market acceptance in opioid addiction treatment, positively impacting the company's overall performance.
- Safety and Tolerability: BXCL501 exhibited a favorable safety and tolerability profile, with lower rates of certain cardiovascular side effects and no reports of sedation in treatment groups, providing strong support for its clinical promotion and reducing potential regulatory hurdles.
- Positive Market Reaction: Following the announcement, BioXcel's shares surged nearly 20% in pre-market trading, reflecting investor optimism regarding the drug's prospects, which could provide additional funding support for the company's future research and development efforts.
See More
Halper Sadeh Investigates BioXcel Therapeutics for Potential Breach of Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. breached their fiduciary duties to shareholders, potentially leading to corporate governance reforms and fund recovery.
- Legal Relief Options: Long-term shareholders of BioXcel stock may seek court-approved financial incentive awards or other relief measures, enhancing shareholder rights and company transparency.
- Importance of Participation: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, thereby increasing management transparency and accountability, which enhances shareholder value.
- Fee Arrangement: Halper Sadeh LLC will handle the case on a contingent fee basis, meaning shareholders will not be responsible for legal fees or expenses, reducing the financial burden of participation.
See More
BioXcel Seeks FDA Approval for At-Home Use of IGALMI® in Agitation Treatment
- Application Progress: BioXcel Therapeutics plans to submit a supplemental New Drug Application (sNDA) this month seeking FDA approval for IGALMI® for at-home use in treating agitation associated with bipolar disorders or schizophrenia, with potential approval as early as 2026, thus providing a much-needed treatment option for patients.
- Market Demand: Currently, there are no FDA-approved options for at-home use of IGALMI® in acute agitation treatment, and BioXcel's application aims to fill this market gap, addressing urgent needs of patients and caregivers, which could significantly enhance the company's market share.
- Technological Innovation: IGALMI® is an orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, and BioXcel is also investigating its use for acute agitation in Alzheimer's and bipolar disorders, showcasing the company's innovative potential in neuroscience.
- Regulatory Support: IGALMI® has received Breakthrough Therapy and Fast Track designations from the FDA, indicating its potential significance in treating acute agitation, further strengthening BioXcel's competitive position in the biopharmaceutical industry.
See More
BIOXCEL THERAPEUTICS STOCK INCREASES 2.7% FOLLOWING POSITIVE RESULTS FROM MID-STAGE TRIAL OF EXPERIMENTAL OPIOID WITHDRAWAL TREATMENT
Stock Performance: BioXcel Therapeutics shares have increased by 2.7%.
Clinical Trial Results: An experimental opioid withdrawal drug shows benefits in mid-stage trials.
See More
BioXcel Therapeutics Shares Decline Despite Positive Drug Development News
- Drug Development Progress: BioXcel Therapeutics' BXCL501 demonstrated efficacy in a Phase 2 study led by Columbia University for treating opioid withdrawal symptoms, with over a 30% reduction in symptoms observed in patients, indicating the drug's potential across multiple indications.
- Stock Price Analysis: Despite the positive results from BXCL501, BioXcel's shares are currently priced at $1.52, trading 3.9% below the 20-day simple moving average and 17.9% below the 100-day SMA, indicating a lack of upward momentum in the short term.
- Long-term Performance Weakness: The stock has decreased approximately 41.24% over the past 12 months and is closer to its 52-week lows, reflecting market concerns about its future performance, although the relative strength index (RSI) at 46.86 suggests a neutral state.
- Market Sentiment Analysis: While the overall trend is bearish, the MACD at -0.0166 is above its signal line, indicating some bullish momentum that may present short-term trading opportunities for investors.
See More
BioXcel Therapeutics Reports Positive Phase 2 Results for Opioid Withdrawal Treatment
- Clinical Trial Results: BioXcel Therapeutics' Phase 2 study indicates that BXCL501 is as effective as or superior to BioCorRx's lofexidine in reducing opioid withdrawal symptoms, with a more convenient dosing regimen potentially offering better treatment options for patients.
- Significant Symptom Improvement: Patients receiving BXCL501 240 µg experienced over a 30% reduction in Short Opiate Withdrawal Scale (SOWS-Gossop) scores, with peak symptom improvement observed on days 3 and 4, demonstrating BXCL501's efficacy.
- Good Tolerability Profile: BXCL501 showed a favorable tolerability profile compared to lofexidine, with similar or lower rates of cardiovascular side effects, indicating higher safety in clinical applications.
- Huge Market Potential: BXCL501 is viewed as a “pipeline within a product,” with applicability potentially extending to acute agitation associated with bipolar disorder and schizophrenia, signaling future market opportunities.
See More
BioXcel Therapeutics Reports Positive Phase 2 Trial Results for Opioid Withdrawal Treatment
- Clinical Trial Results: BioXcel Therapeutics announced positive topline results from a Phase 2 trial involving 80 patients, where BXCL501 demonstrated a significant reduction of over 30% in opioid withdrawal symptoms, indicating its potential effectiveness comparable to or better than FDA-approved lofexidine, thereby strengthening the company's competitive position in the market.
- Notable Treatment Effects: The most significant symptom improvement was observed on days three and four of treatment, which not only enhances BXCL501's clinical application potential but may also increase its market acceptance in opioid addiction treatment, positively impacting the company's overall performance.
- Safety and Tolerability: BXCL501 exhibited a favorable safety and tolerability profile, with lower rates of certain cardiovascular side effects and no reports of sedation in treatment groups, providing strong support for its clinical promotion and reducing potential regulatory hurdles.
- Positive Market Reaction: Following the announcement, BioXcel's shares surged nearly 20% in pre-market trading, reflecting investor optimism regarding the drug's prospects, which could provide additional funding support for the company's future research and development efforts.
See More
Halper Sadeh Investigates BioXcel Therapeutics for Potential Breach of Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. breached their fiduciary duties to shareholders, potentially leading to corporate governance reforms and fund recovery.
- Legal Relief Options: Long-term shareholders of BioXcel stock may seek court-approved financial incentive awards or other relief measures, enhancing shareholder rights and company transparency.
- Importance of Participation: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, thereby increasing management transparency and accountability, which enhances shareholder value.
- Fee Arrangement: Halper Sadeh LLC will handle the case on a contingent fee basis, meaning shareholders will not be responsible for legal fees or expenses, reducing the financial burden of participation.
See More
BioXcel Seeks FDA Approval for At-Home Use of IGALMI® in Agitation Treatment
- Application Progress: BioXcel Therapeutics plans to submit a supplemental New Drug Application (sNDA) this month seeking FDA approval for IGALMI® for at-home use in treating agitation associated with bipolar disorders or schizophrenia, with potential approval as early as 2026, thus providing a much-needed treatment option for patients.
- Market Demand: Currently, there are no FDA-approved options for at-home use of IGALMI® in acute agitation treatment, and BioXcel's application aims to fill this market gap, addressing urgent needs of patients and caregivers, which could significantly enhance the company's market share.
- Technological Innovation: IGALMI® is an orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, and BioXcel is also investigating its use for acute agitation in Alzheimer's and bipolar disorders, showcasing the company's innovative potential in neuroscience.
- Regulatory Support: IGALMI® has received Breakthrough Therapy and Fast Track designations from the FDA, indicating its potential significance in treating acute agitation, further strengthening BioXcel's competitive position in the biopharmaceutical industry.
See More
